Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
439
archived clinical trials in
Eating Disorder

A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Boston Clinical Trials, INC.
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research
mi
from
Methuen, MA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Adams Clinical Trials LLC
mi
from
Watertown, MA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Adams Clinical Trials LLC
mi
from
Watertown, MA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
ActivMed Practice and Research, Inc
mi
from
Portsmouth, NH
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
ActivMed Practice and Research, Inc
mi
from
Portsmouth, NH
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Oregon Center for Clinical Investigations, Inc
mi
from
Salem, OR
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Lehigh Center for Clinical Research
mi
from
Allentown, PA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Texas Center for Drug Development, P.A.
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Institute for Advanced Medical Research at Mercer University
mi
from
Atlanta, GA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Institute for Advanced Medical Research at Mercer University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Donald J. Garcia, MD, PA
mi
from
Austin, TX
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Donald J. Garcia, MD, PA
mi
from
Austin, TX
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Marcos, CA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Marcos, CA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Connecticut Clinical Research
mi
from
Cromwell, CT
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Connecticut Clinical Research
mi
from
Cromwell, CT
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Manhattan Behavior Medicine
mi
from
New York, NY
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Manhattan Behavior Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Pillar Clinical Research, LLC
mi
from
Richardson, TX
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Pillar Clinical Research, LLC
mi
from
Richardson, TX
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Rocheser Center for Behavioral Medicine
mi
from
Rochester Hills, MI
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Rocheser Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
Phoenix Medical Research
mi
from
Prairie Village, KA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research
mi
from
Prairie Village, KA
Click here to add this to my saved trials
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  12/31/1969
McLean Hospital Harvard Medical School
mi
from
Belmont, MA
A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder
A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 12/31/1969
McLean Hospital Harvard Medical School
mi
from
Belmont, MA
Click here to add this to my saved trials
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Duke University Health System
mi
from
Durham, NC
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population
Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology
Status: Enrolling
Updated:  10/3/2008
Penn State College of Medicine
mi
from
Hershey, PA
The Effects of Written Emotional Disclosure on Eating Disorder Pathology in a Clinical Eating Disordered Population
Study of the Efficacy of Written Emotional Disclosure on Eating Disorder Pathology
Status: Enrolling
Updated: 10/3/2008
Penn State College of Medicine
mi
from
Hershey, PA
Click here to add this to my saved trials
Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa
Treatment of Bulimia Nervosa: Dysregulated Subtype
Status: Enrolling
Updated:  4/29/2009
Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Focused Versus Enhanced Cognitive Behavioral Therapy for Treating Women With Bulimia Nervosa
Treatment of Bulimia Nervosa: Dysregulated Subtype
Status: Enrolling
Updated: 4/29/2009
Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder
Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity
Status: Enrolling
Updated:  4/11/2012
Lindner Center of HOPE
mi
from
Mason, OH
Efficacy Study of Lisdexamfetamine to Treat Binge Eating Disorder
Lisdexamfetamine in Binge Eating Disorder of Moderate or Greater Severity
Status: Enrolling
Updated: 4/11/2012
Lindner Center of HOPE
mi
from
Mason, OH
Click here to add this to my saved trials
Characteristics and Importance of Physical Activity in Women With Anorexia Nervosa
Physical Activity in Anorexia Nervosa: Characteristics and Clinical Significance
Status: Enrolling
Updated:  5/1/2013
New York State Psychiatric Institute
mi
from
New York, NY
Characteristics and Importance of Physical Activity in Women With Anorexia Nervosa
Physical Activity in Anorexia Nervosa: Characteristics and Clinical Significance
Status: Enrolling
Updated: 5/1/2013
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity
Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity
Status: Enrolling
Updated:  11/4/2013
Duke University Health System
mi
from
Durham, NC
Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity
Eating Disorders in Type 1 Diabetes: Mechanisms of Comorbidity
Status: Enrolling
Updated: 11/4/2013
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Engaging Latino Families in Eating Disorders Treatment
Engaging Latino Families in Eating Disorders Treatment
Status: Enrolling
Updated:  7/22/2014
UNC Center of Excellence for Eating Disorders
mi
from
Chapel Hill, NC
Engaging Latino Families in Eating Disorders Treatment
Engaging Latino Families in Eating Disorders Treatment
Status: Enrolling
Updated: 7/22/2014
UNC Center of Excellence for Eating Disorders
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Engaging Latino Families in Eating Disorders Treatment
Engaging Latino Families in Eating Disorders Treatment
Status: Enrolling
Updated:  7/22/2014
Univ of North Carolina
mi
from
Chapel Hill, NC
Engaging Latino Families in Eating Disorders Treatment
Engaging Latino Families in Eating Disorders Treatment
Status: Enrolling
Updated: 7/22/2014
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated:  11/5/2014
University of Michigan
mi
from
Ann Arbor, MI
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated: 11/5/2014
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated:  11/5/2014
Bard College
mi
from
Annandale-on-Hudson, NY
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated: 11/5/2014
Bard College
mi
from
Annandale-on-Hudson, NY
Click here to add this to my saved trials
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated:  11/5/2014
Appalachian State University
mi
from
Boone, NC
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated: 11/5/2014
Appalachian State University
mi
from
Boone, NC
Click here to add this to my saved trials
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated:  11/5/2014
Mercyhurst University
mi
from
Erie, PA
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
A Novel Intervention Promoting Eating Disorder Treatment Among College Students
Status: Enrolling
Updated: 11/5/2014
Mercyhurst University
mi
from
Erie, PA
Click here to add this to my saved trials
Armodafinil in Binge Eating Disorder (BED)
Status: Enrolling
Updated:  5/13/2015
Lindner Center of HOPE
mi
from
Mason, OH
Armodafinil in Binge Eating Disorder (BED)
Status: Enrolling
Updated: 5/13/2015
Lindner Center of HOPE
mi
from
Mason, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Study Centers, LLC
mi
from
Little Rock, AR
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Study Centers, LLC
mi
from
Little Rock, AR
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Pacific Research Partners, LLC
mi
from
Oakland, CA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Pacific Research Partners, LLC
mi
from
Oakland, CA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Research Across America
mi
from
Santa Ana, CA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Research Across America
mi
from
Santa Ana, CA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Gulfcoast Clinical Research
mi
from
Fort Myers, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Uptown Research Institute, Llc
mi
from
Chicago, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Uptown Research Institute, Llc
mi
from
Chicago, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Alexian Brothers Behavioral Health Hospital
mi
from
Hoffman Estates, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Alexian Brothers Behavioral Health Hospital
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
AMR Baber Research Inc.
mi
from
Naperville, IL
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
AMR Baber Research Inc.
mi
from
Naperville, IL
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Goldpoint Clinical Research
mi
from
Indianapolis, IN
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Cypress Medical Research Center, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
McLean Hospital
mi
from
Belmont, MA
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
McLean Hospital
mi
from
Belmont, MA
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Pacific Research for Research and Evaluation
mi
from
Albuquerque, NM
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Pacific Research for Research and Evaluation
mi
from
Albuquerque, NM
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
Community Research
mi
from
Cincinnati, OH
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
Community Research
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated:  11/3/2015
IPS Research Company
mi
from
Oklahoma City, OK
SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder
Status: Enrolling
Updated: 11/3/2015
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials